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Introduction
Acute mountain sickness (AMS) occurs in up to 50% of individuals ascending to high altitude (Maggiorini et al., 1990) and may progress to life-threatening pulmonary and cerebral oedema in a minority of cases (Roach, and Hackett, 2001 ). The present international consensus defines AMS as a collection of subjective, non-specific symptoms (Roach et al., 1993) . Specifically, headache, sleep disturbance, and vague symptoms of fatigue and dizziness and given equal diagnostic weighting. Since we lack a common underlying mechanism to explain these symptoms, it is far from certain that they belong together as a single syndrome.
The most frequently-used criteria for the definition of AMS are based on the selfreported Lake Louise consensus scoring system (LLS) (Roach et al., 1993) . A positive Lake Louise Score can describe a spectrum of non-specific symptoms experienced on exposure to high altitude, and these may encompass more than one disease phenotype (West, 2011) .
Headache is the cardinal feature of the LLS and is required under the present criteria for diagnosis of AMS (Roach et al., 1993) . There is evidence to suggest that the development of mild vasogenic cerebral oedema leading to increased intracranial pressure may be an important factor in the development of high altitude headache and AMS (Kallenberg et al., 2007) . Optic nerve sheath diameter, an indirect measure of intracranial pressure, increases with altitude and also correlates with AMS score (Fagenholz et al., 2009; Sutherland et al., 2008) . Several small case series in which participants were subjected to simulated high altitude before undergoing cerebral MRI also demonstrated an Page 5 of 30 increase in brain volume (Kallenberg et al., 2007; Morocz et al., 2001) . A related hypothesis proposes that fluid redistribution to the intracellular space leading to astrocytic swelling underlies the development of symptomatic AMS (Bailey et al., 2009 ).
In contrast, sleep disturbance at high altitude may be a mechanistically separate problem. Changes in the control of ventilation following acute ascent to altitude lead to a cyclical respiratory pattern. The hypoxic ventilatory drive causes hypocapnia and a reduction in respiratory drive (Wilson et al., 2009) . During sleep, in the absence of the wakefulness drive to breathing, hypoventilation results in cyclical hypoxia and recurrent interruption of deep sleep stages (Burgess et al., 2004) .
As a categorical score, LLS is inherently disadvantaged in any attempt to quantify a continuous spectrum of disease severity. A further problem in the measurement of AMS is that LLS scores at high altitude produce a strongly skewed dataset, reducing the power of statistical analyses and making it difficult to quantitatively compare different symptoms, or to infer relationships between severity and other physiological or biochemical measurements.
Visual analogue scales (VAS) have been rigorously validated as tools to quantify the severity of subjective symptoms, particularly in pain medicine (DeLoach et al., 1998; Gallagher et al., 2001; Price et al., 1983; Todd et al., 1996) , and are increasingly accepted for symptom scoring at altitude (Roach, and Kayser, 2007) . Harris et al. used VAS scores as an endpoint in a randomised controlled trial comparing treatments of high altitude headache (Harris et al., 2003) . Since then, there have been four studies exploring the relationship between VAS and LLS describing altitude symptomatology Page 6 of 30 (Hext et al., 2011; Kayser et al., 2010; Van Roo et al., 2011; Wagner et al., 2007) , consistently demonstrating a correlation between LLS and VAS, both for individual components of LLS and overall LLS score. However, both the linearity of the relationship and the threshold VAS measurement for diagnosis of AMS are poorly defined. Unlike LLS, which is a standardised score and comparable across different studies, VAS studies have used different scores and as yet there is no consensus VAS for altitude illness.
We sought to perform an unbiased quantitative assessment of the symptomatology of AMS in healthy lowlanders acutely exposed to high altitude. We used a novel VAS questionnaire to record subjective symptoms experienced by research subjects over the course of 1110 subject-days at high altitude. Here we report the comparison between VAS and LLS, and apply a hypothesis-free clustering methodology widely used in transcriptomics to identify different patterns of symptoms in individuals acutely exposed to high altitude.
Materials and Methods

Study Population
Data were collected from subjects at high altitude during two research expeditions. 103 participants were recruited from the Apex 2 expedition to the Bolivian Andes (Baillie et al., 2009; Bates et al., 2011; Thompson et al., 2006) . Subjects flew to La Paz, Bolivia 
Measurement of symptoms
Subjects were asked to complete a novel seven-question visual analogue scale (VAS) questionnaire during acute exposure to high altitude (conceived and designed by DJC, and provided in the Supplementary figure S1 ). This assesses five symptoms associated with high altitude: headache ("no headache at all" to "worst headache ever"), nausea (1. "I really want to be sick" to "don't feel sick at all"; 2."my guts are really bad" to "my guts are fine"), fatigue (1. "I'm totally exhausted" to "I'm full of energy"; 2. "I'm at my best" to "I'm at my worst"), dizziness ("no dizziness at all" to "more dizzy than ever") and sleep quality ("worst night's sleep ever" to "best night's sleep ever"). Subjects were asked to score their symptoms on a spectrum between the two extreme statements by marking their position on a horizontal 100 mm line. On all questionnaires, the direction of the scales was reversed for several questions to ensure subjects paid close attention to the questions. Reversed VAS scales were corrected prior to analysis, such that 0mm
Page 8 of 30 corresponded to minimal severity and 100 mm to maximal severity for all seven questions. Summing the seven components produced a maximum total VAS score of 700 mm. The VAS included a quality control question, which asked with different wording about symptoms of fatigue in order to detect inattentive subjects. A minimum agreement of 40 mm was required between the responses to two questions ("I'm totally exhausted" to "I'm full of energy", and "I'm at my best" to "I'm at my worst").
Subjects also completed the Lake Louise Score (LLS) questionnaire, which includes assessment of headache, nausea and vomiting, fatigue/weakness, dizziness and sleep quality. Participants score the severity of each symptom from 0 (no symptom) to three (maximal severity); a total score of greater than or equal to three with the presence of headache equates to acute mountain sickness (Roach et al., 1993) .
Sequential LLS and VAS data were collected daily from each of the 103 Apex 2 subjects over 13 days of exposure to high altitude (5 days at 3600 m, 8 days at 5200 m). Crosssectional data from the 189 Kilimanjaro subjects were recorded at 4730 m during their ascent.
Data Analysis
VAS scores were measured by hand in mm. Groups of VAS questionnaires exhibiting similar symptom profiles were identified using a network analysis tool, BioLayout Express 3D, http://www.biolayout.org/ (Theocharidis et al., 2009 ). This software is primarily used to visualize and cluster networks from microarray expression data (Freeman et al., 2007) . We created an undirected network, in which each node 
Cluster Analysis of AMS Symptoms
In order to maximise the power to detect different patterns of associated symptoms, we chose a composite analysis, including all questionnaires from within 1 week of a recent increase in altitude. This combined data from disparate sources, with differences in mode and rate of ascent, geographical location and drug treatment, and includes several questionnaires from the same volunteers at different times. The patterns reported here are consistently replicated in subsets of volunteers with same location and ascent rate (Supplementary figure S4) , from the placebo group only and including only one questionnaire for each volunteer (Supplementary figure S3) .
In order to explore different patterns of related symptoms, VAS data for the 1045 subjects-days at altitude were analysed in BioLayout Express 3D. The network generated was clustered using the MCL clustering algorithm (inflation value 1.4, minimum cluster size 30 nodes) producing three main clusters (Figure 3 ). The largest cluster contained 407 questionnaires, and corresponded to subjects who slept poorly, were fatigued, but had minimal headache or other symptoms. The second cluster of 127 questionnaires, contained subjects who reported, poor sleep, headache, and fatigue.
The third cluster contained 43 questionnaires and corresponded to subjects who had little sleep disturbance, but had headache and fatigue. The remaining questionnaires did not form a cluster large enough to be included in the analysis -the full dataset may be Page 11 of 30 explored at www.altitude.org/ams.php. No relationship was seen between age or sex and any pattern of symptoms (Figure 4 ).
Symptom Correlation
The relationship between different symptoms (rather than symptom profiles) was also investigated using the correlation between two symptoms across the whole population of responses. Symptoms as recorded by the visual analogue scale inter-correlated as shown in Table 1 . Sleep was most weakly correlated with the five other symptoms (mean correlation co-efficient 0.33), whereas fatigue was most strongly correlated with the other reported symptoms (mean correlation co-efficient 0.55). A network showing the relationship between symptoms is shown in Figure 5 .
Timing of sleep assessment
For practical reasons, AMS questionnaires inquire about sleep quality on the night preceding the questionnaire. This is one reason why AMS scores are lower on the first day following acute ascent. However in physiological terms it is equally logical to assess sleep on the following night. This is particularly important when assessing the correlation of sleep with other symptoms, because the better sleep quality experienced on the night before ascent will cause an artefactual dissociation between sleep quality and the other symptoms of AMS.
Our dataset enables us to address the effect of this change. We repeated the correlation analyses on a subset of questionnaires in which we substituted the sleep score from the following day. For both the clustering of questionnaires with similar patterns of symptoms (Supplementary figure S3) , and the correlation between the 5 symptoms across all volunteers, the patterns described above were consistently replicated.
Quantification of severity
384 of the 1045 questionnaires were consistent with a diagnosis of acute mountain sickness using the Lake Louise Score (LLS > 2 with LLS headache > 0). One subject developed high altitude pulmonary edema (HAPE) at 3600m; there were no cases of HACE (high altitude cerebral edema). The median of all LLS scores was 2 (interquartile range 1-4). The mean total VAS was 192.6 mm with a standard deviation of 124.3 mm.
A square-root transformation resulted in normalisation of the VAS data (KolmogorovSmirnov test: KS distance 0.02036, P>0.10) but not the LLS data (Kolmogorov-Smirnov test: KS distance 0.1620, P<0.0001) (Figure 2 ).
Discussion and Conclusion
The scale of the dataset collated here, collected during 1110 subject-days at altitude, enables for the first time a comprehensive quantitative analysis of symptom correlation in altitude illness. We show that sleep disturbance is an outlier, correlating poorly with other symptoms of AMS. By identifying clusters sharing common patterns of symptoms, we demonstrate that distinct patterns of disease are primarily characterised by the presence of sleep disturbance or headache.
Among symptomatic individuals following acute ascent to high altitude, some degree of fatigue was a ubiquitous finding. In contrast, sleep disturbance and headache are each commonly reported without the other. This is consistent with the hypothesis that distinct pathogenetic mechanisms underlie sleep disturbance and headache at high altitude.
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Analysis of correlation networks is a standard tool for drawing biological meaning from transcriptomic data Mabbott et al., 2010; Summers et al., 2010 ). As we demonstrate here, the same approach may also have substantial utility in classifying disease phenotypes. By providing an unbiased allocation of subjects with similar symptoms into clusters, it provides a novel and informative method for identifying patterns of disease. This method may easily be extended to other syndromes.
Our primary dataset contains repeated measures (1110 questionnaires obtained from 292 subjects), which may lead to a learning bias in subjects completing the VAS (Van Roo et al., 2011) . We also used symptom scores from some subjects who were taking oral antioxidant supplements or sildenafil for other trials. However these limitations do not affect the main outcomes. Repeat analyses focussing only on a single time point, or removing subjects on active drug treatments, did not affect the results.
Our study makes use of the largest VAS dataset to date to explore altitude-associated symptomatology. As expected, there is a strong correlation between VAS and LLS (Hext et al., 2011; Kayser et al., 2010; Van Roo et al., 2011; Wagner et al., 2007) . Our work extends previous attempts to evaluate VAS scores by demonstrating the utility of VAS in creating a normally-distributed, continuous measure of AMS. VAS have a high test-retest reliability and inter-rater reliability (Roach, and Kayser, 2007) and may be more sensitive than discrete measures (Grant et al., 1999) . In future research using VAS as an endpoint or covariate, improved statistical power may be expected from the use of parametric tests that may only be applied to normally-distributed, continuous variables.
Furthermore, combining distinct pathophysiological processes into a single summary measure carries a risk of introducing excessive noise into studies of the pathogenesis of AMS, and of reducing the magnitude of effect signals in therapeutic studies. Focussing only on a group of well-correlated symptoms that share common mechanisms will further improve the quality of future research into AMS.
To be useful for clinical and physiological studies, a symptom score must accurately reflect the severity of a single clinical entity (Bartsch et al., 2004) . It is therefore critical that all of the symptoms included share an underlying pathogenesis. If not, effective treatments will be falsely rejected, and attempts to understand disease processes will be obstructed. It is our view that the results presented here should provoke a reassessment of consensus diagnostic criteria and severity measures for AMS.
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